Salt form and crystal form serving as FGFR and VEGFR inhibitor compounds, and preparation method therefor

A crystal form of a compound of formula (II), (III), or (IV):

• wherein the crystal form is a crystal form G of the compound of formula (II) or a crystal form I of the compound of formula (III) or a crystal form J of the compound of formula (IV), wherein:
• the X-ray powder diffraction pattern of the crystal form G of the compound of formula (II) comprises characteristic diffraction peaks at the following angle 2θ:
• 7.39±0.2°, 19.07±0.2°, and 20.04±0.2°;
• the X-ray powder diffraction pattern of the crystal form I of the compound of formula (III) comprises characteristic diffraction peaks at the following angle 2θ:
• 6.73±0.2°, 11.66±0.2°, and 19.51±0.2°;
• and the X-ray powder diffraction pattern of the crystal form J of the compound of formula (IV) comprises characteristic diffraction peaks at the following angle 2θ:
• 4.99±0.2°, 11.32±0.2°, and 19.95±0.2°.